found four target proteins related to AD and two pathways related to neuroinflammation through network pharmacology, and speculated that HLJDD may exert its anti-AD effect by scavenging/reducing Aβ in the brain and inhibiting hyperphosphorylation of tau protein through insulin signaling pathway (Sun et al., 2017). Here, MAPT is linked to Alzheimer disease.